Active Studies

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the
efficacy and safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified
(IGIV-C) as a corticosteroid (CS)-sparing agent in subjects with CS-dependent Myasthenia
Gravis (MG).

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo
works in treating patients with stage IB-IIIA non-small cell lung cancer that has been
completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.

The purpose of this study is to evaluate the safety and pharmacokinetics ASG-22CE as well as
assess the immunogenicity and antitumor activity in subjects with metastatic urothelial
cancer and other malignant solid tumors.

This is a clinical research study of an investigational (FDA IND-BB 10091) treatment for
patients with advanced colorectal cancer that no longer responds to standard therapies.

The treatment is being evaluated for its effect on tumor growth. It consists of small beads
that contain mouse cancer cells from a mouse kidney cancer cell line. The cells in the beads
produce substances that have been shown to slow or stop the growth of tumors in experimental
animals, veterinary patients, and 37 humans with colorectal cancers in a Phase 1 and 2
safety trials.

This randomized phase III trial studies standard or comprehensive radiation therapy in
treating patients with early-stage breast cancer who have undergone surgery. Radiation
therapy uses high-energy x rays to kill tumor cells. It is not yet known whether
comprehensive radiation therapy is more effective than standard radiation therapy in
treating patients with breast cancer